Mavenclad is an oral treatment for relapsing MS and active secondary progressive MS.
- Family Elder
- Posts: 361
- Joined: Thu Nov 26, 2009 3:00 pm
- Location: Melbourne, Australia
Merck Serono, makers of leukemia drug Cladribine (now marketed as MS drug Movectro) have been fined A$75,000 for breach of the Medicines Australia Code of Conduct for their Movectro advertisement on the Australian Channel 7 news last year. The advertisement was presented as a news item, and was performed by neurologist Dr Bill Carroll (Multiple Sclerosis Research Australia) and MS Australia.
In Australia, it is not legal to advertise a prescription medication direct to the consumer.
I’m sure Merck Serono still view this as cheap advertising.